The very tools that accelerate discovery can also introduce new risks of accidental release or deliberate misuse of ...

Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer (NSCLC) CHICAGO, Sept. 05, 2025 (GLOBE ...

LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical ...

The 1,115-foot-wide (340 meters) asteroid Apophis will pass closer to Earth than many satellites fly in April 2029, giving ...

LONDON, GREATER LONDON, UNITED KINGDOM, September 18, 2025 /EINPresswire.com/ -- How Big Is The Microorganism Feed Carbohydrase Market In 2025? The microorganism feed carbohydrase market size has ...

Estimated median progression free survival (PFS) in third-line treatment (180 mg dose) was 5.6 months. The comparable PFS threshold in standard of care treatments is 2.5 months 1.

Brexit is 'leaving behind an entire generation' of young people, according to a senior German politician who said Scotland would be welcomed ...

Public and private investment serve different purposes. NIH funding often reduces scientific risk by advancing projects to a ...

Nautilus Biotechnology, Inc. ( NASDAQ: NAUT) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:50 PM EDT Hello. Hi. My name is Yuko Oku, and I work on the Life Science Tools ...

AI is driving exponential growth in sustainable bioprocessing and automation through computational advances and collaboration.

LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it ...

MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies ...